Abstract
The Dutch retinoblastoma registry was used to analyze risks of second primary malignancies in retinoblastoma patients diagnosed from 1945 to 2005. After extensive follow-up procedures, complete follow-up data of 668 (89%) retinoblastoma patients were obtained. Information of current health, past diseases, including any occurrence of cancer, medical treatments, and various risk factors for cancer were obtained by means of a mailed questionnaire and confirmed by pathology reports, hospital or physician’s records. For both hereditary and nonhereditary retinoblastoma patients, risks of second primary malignancies were compared with the Dutch general population. No statistically significantly elevated risks of second primary malignancies were found among nonhereditary retinoblastoma survivors (standardized incidence rate (SIR) = 1.86; 95% confidence interval (CI): 0.96–3.24, absolute excess risk (AER) = 0.57 per 1,000 person-years). Among hereditary retinoblastoma survivors an overall risk of 20.4 (95% CI: 15.6–26.1; AER = 8.61 per 1,000 person-years) was found, which increased almost with threefold when these patients were treated with radiotherapy. Because of the small number of hereditary retinoblastoma patients treated with chemotherapy exclusively, our ability to detect any association of chemotherapy with second solid malignancy was limited. Among hereditary retinoblastoma patients, the cumulative incidence of a second malignancy at 40 years after retinoblastoma diagnosis, accounting for death as a result of other causes as competing risk, was 28% (95% CI: 21.0–35%). Our results confirmed the strongly increased risks of soft tissue sarcoma, osteosarcoma, and melanoma in hereditary retinoblastoma survivors. However, after more than 40 years of follow-up an emerging excess of epithelial cancers (i.e., breast, lung and bladder) was observed, which had not been reported in other long-term follow-up studies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abramson DH, Melson MR, Dunkel IJ, Frank CM (2001) Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 108:1868–1876
Der Kinderen DJ, Koten JW, Nagelkerke NJ, Tan KE, Beemer FA, Den Otter W (1988) Non-ocular cancer in patients with hereditary retinoblastoma and their relatives. Int J Cancer 41:499–504
Draper GJ, Sanders BM, Kingston JE (1986) Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661–671
Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, Seddon J, Tarbell N, Boice JD Jr (1993) Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85:1121–1128
Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J (2004) Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96:357–363
Forrest AW (1961) Tumors following radiation about the eye. Trans Am Acad Ophthalmol Otolaryngol 65:694–717
Helman LJ, Meltzer P (2003) Mechanisms of sarcoma development. Nat Rev Cancer 3:685–694
Horowitz JM, Park SH, Bogenmann E, Cheng JC, Yandell DW, Kaye FJ, Minna JD, Dryja TP, Weinberg RA (1990) Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA 87:2775–2779
Kannan K, Sharpless NE, Xu J, O’Hagan RC, Bosenberg M, Chin L (2003) Components of the Rb pathway are critical targets of UV mutagenesis in a murine melanoma model. Proc Natl Acad Sci USA 100:1221–1225
Kansara M, Thomas DM (2007) Molecular pathogenesis of osteosarcoma. DNA Cell Biol 26:1–18
Kleinerman RA, Tarone RE, Abramson DH, Seddon JM, Li FP, Tucker MA (2000) Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst 92:2037–2039
Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, Li FP, Fraumeni JF Jr (2005) Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23:2272–2279
Kleinerman RA, Tucker MA, Abramson DH, Seddon JM, Tarone RE, Fraumeni JF Jr (2007) Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99:24–31
Knudson AG Jr, Meadows AT, Nichols WW, Hill R (1976) Chromosomal deletion and retinoblastoma. N Engl J Med 295:1120–1123
Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE (2008) Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100:1771–1779
Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ, Moll AC (2009) Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 45:3245–3253
Marees T, van Leeuwen FE, Schaapveld M, Imhof SM, de Boer MR, Kors WA, Ringens PJ, Moll AC (2010) Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer. Apr 16 (in press)
Mitra AP, Birkhahn M, Cote RJ (2007) p53 and retinoblastoma pathways in bladder cancer. World J Urol 25:563–571
Moll AC, Imhof SM, Bouter LM, Kuik DJ, Den Otter W, Bezemer PD, Koten JW, Tan KE (1996) Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945–1994. Int J Cancer 67:515–519
Moll AC, Imhof SM, Bouter LM, Tan KE (1997a) Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet 18:27–34
Moll AC, Kuik DJ, Bouter LM, Den Otter W, Bezemer PD, Koten JW, Imhof SM, Kuyt BP, Tan KE (1997b) Incidence and survival of retinoblastoma in The Netherlands: a register based study 1862–1995. Br J Ophthalmol 81:559–562
Reese A, Merriam G, Martin H (1949) Treatment of bilateral retinoblastoma by irradiation and surgery: report on fifteen years results. Am J Ophthalmol 32:175–190
Roarty JD, McLean IW, Zimmerman LE (1988) Incidence of second neoplasms in patients with bilateral retinoblastoma. Ophthalmology 95:1583–1587
Tucker MA, D’Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W, Hoover RN, Fraumeni JF Jr, The Late Effects Study Group (1987) Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 317:588–593
van der Sanden GA, Coebergh JW, Schouten LJ, Visser O, van Leeuwen FE (1995) Cancer incidence in The Netherlands in 1989 and 1990: first results of the nationwide Netherlands cancer registry. Coordinating Committee for Regional Cancer Registries. Eur J Cancer 31A:1822–1829
Vogel F (1979) Genetics of retinoblastoma. Hum Genet 52:1–54
Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP (1997) Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278:1262–1267
Yang G, Rajadurai A, Tsao H (2005) Recurrent patterns of dual RB and p53 pathway inactivation in melanoma. J Invest Dermatol 125:1242–1251
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Moll, A.C., Marees, T., Bosscha, M.I., van Leeuwen, F.E. (2012). Long-Term Survivors of Retinoblastoma: Risk of Increased Second Malignancy. In: Hayat, M. (eds) Tumors of the Central Nervous System, Volume 8. Tumors of the Central Nervous System, vol 8. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4213-0_15
Download citation
DOI: https://doi.org/10.1007/978-94-007-4213-0_15
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-4212-3
Online ISBN: 978-94-007-4213-0
eBook Packages: MedicineMedicine (R0)